key: cord-0978765-e1pavunq
authors: Lafon, Eliott; Jäger, Michael; Bauer, Angelika; Reindl, Markus; Bellmann-Weiler, Rosa; Wilflingseder, Doris; Lass-Flörl, Cornelia; Posch, Wilfried
title: Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern
date: 2022-01-29
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2022.01.013
sha: e92699a0d41a1861df42614451e8f08152276d38
doc_id: 978765
cord_uid: e1pavunq

Background Only a few studies directly compared virus-specific antibodies and their neutralizing capacity against SARS-CoV-2 wild type and circulating variants of concern, despite the reported high efficacy of mRNA- and vector-based vaccines. Objective Here we assessed SARS-CoV-2-S1-specific antibodies of BNT162b2, mRNA-1273 and ChAdOx1 vaccinated as well as convalescent COVID-19 patients and furthermore determined the neutralization ability against SARS-CoV-2 wild type and B.1.1.7 (Alpha), B1.1.7 E484K (Alpha E484K), B.1.351 (Beta) and B.1.617.2 (Delta) variants. Methods Serum samples of 107 fully vaccinated or convalescent individuals were analyzed for anti-SARS-CoV-2-S1 IgG and IgA as well as for total anti-SARS-CoV-2 RBD Ig. Furthermore, neutralization capacity as NT50 and NT90 values against SARS-CoV-2 wild type virus and circulating variants were determined. Results We observed a robust IgG response in all participants, however the highest titers were detected in mRNA-based vaccine recipients. In case of serum IgA responses, the difference between mRNA- and vector-based vaccines or convalescent patients was even more pronounced. Interestingly, all three vaccines could neutralize all tested VOCs in addition to wild type virus, but in some individuals only low or no neutralization especially against Alpha-E484K and Delta variant was detected. Conclusion Critically, we here studied the efficacy of various COVID-19 vaccines and found that mRNA-1273 had the highest neutralization abilities compared to BNT162b2- and ChAdOx1 vaccinees. COVID-19 convalescent patients demonstrated the most heterogeneous range of antibody titers and neutralization ability, rendering assessment of protection difficult. Furthermore a significant, positive relation between antibodies and NT50 values for immunized and convalescent individuals was determined.

WT wild type The current COVID-19 pandemic caused by Severe Acute Respiratory Syndrome 129

CoV-2-specific IgG (Fig. 1A , above) and IgA (Fig. 1B , above) antibodies against the S1 287 region of the SARS-CoV-2 spike protein in serum samples. In addition, total SARS-CoV-288 2-specific Igs (Fig. 1C , above) against the receptor binding domain (RBD) of the viral spike 289 protein were determined. These analyses revealed that 100% of individuals vaccinated 290 with mRNA vaccines BNT162b2 and mRNA-1273 were tested positive for IgGs against 291 S1 region (Fig. 1A, below) . In contrast 97% of vector-based vaccine ChAdOx1 and only 292 62.5% patients of the convalescent group were positive for IgGs (Fig. 1A, below, 293 ChAdOx1 and convalescent). Similar to IgGs, also 100% BNT162b2 vaccinated 294 participants were positive for serum IgA. 84.2%, 50% and 16.7% tested positive for serum 295

IgA in the mRNA-1273, ChAdOx1 and convalescent group, respectively (Fig. 1B, below) . 296

Further analyses showed that median antibody titers of SARS-CoV-2-specific IgG and IgA 297 were significantly higher in individuals vaccinated with mRNA-based vaccines such as 298 BNT162b2 (IgG: 679.0; 95% confidence interval (CI) 626.1 -733.7; IgA: 5.3; 95% CI 3.9 299 -7.1) and mRNA-1273 (IgG: 618.6; 95% CI 492.4 -672.9; IgA: 3.9; 95% CI 0.9 -6.0) 300 compared to vector-based vaccine ChAdOx1 (IgG: 259.5; 95% CI 181.3 -337.9; IgA: 0.7; 301 95% CI 0.6 -1.4) or detected in convalescent patients (IgG: 41.8; 95% CI 17.6 -77.6; 302

IgA: 0.6; 95% CI 0.4 -1.0) (Fig. 1A+B , above; Tab. S5). Significant differences were also 303 found between the mRNA-based vaccines in induction of SARS-CoV-2-specific IgA, but 304 not IgG levels against the S1 region ( Fig. 1A+B , above; BNT162b2 vs. mRNA-1273). 305

Analyses of total SARS-CoV-2-specific Igs against the RBD region of the spike protein 306 demonstrated that 100% of vaccinated and 91.7% of convalescent COVID-19 patients 307 were tested positive (Fig 1C, below) . No significant differences were detected here 308 between the three vaccinated groups (ChAdOx1: 18.4; 95% CI 17.9 -18.7; BNT162b2: 309 18.0; 95% CI 17.5 -18.7; mRNA-1273: 18.5; 95% CI 18.1 -18.7), but total Igs levels 310

were significantly lower in convalescence (15.5; 95% CI 6.4 -17.0) compared to 311 vaccinated individuals (Fig. 1C , above; Tab. S5). Furthermore, we investigated sex-312 specific differences for SARS-CoV-2-specific IgG, IgA and total Igs induced in vaccinated 313 and convalescent individuals, but no significant differences were found (Fig. S1) . 314

Subsequently, we aimed to determine the neutralizing activity of individuals vaccinated 316 with the vector-based vaccine ChAdOx1. In this regard, serum samples were incubated 317 in various concentrations with the original viral strain and circulating variants that emerged 318 since the end of 2020. Among these variants were SARS-CoV-2 Alpha-, Beta-, Alpha-319

We calculated half maximal neutralization titers (NT50) and found that 96.2%, 96.2%, 321 88.5%, 88.5% and 69.2% of ChAdOx1 vaccinated individuals could neutralize SARS-322

CoV-2 WT strain, Alpha-, Alpha-E484K-, Beta-and Delta virus variant respectively (Fig. 323 2A) . NT50 values were calculated from neutralization curves using four-parameter 324 nonlinear regression and a median neutralization curve of each virus is shown in Fig. 2B 

Results from antibody titers and neutralization assays (NT50 values) observed in 404 COVID-19 vaccinated or convalescents individuals were statistically analyzed to identify 405 a correlation between higher amounts of IgA or IgG antibodies and enhanced 406 neutralization of SARS-CoV-2 WT strain. Therefore, we next performed correlation 407 analyzes between antibody titers and corresponding NT50 values from each study 408 participants using two-tailed nonparametric Spearman correlation. For ChAdOx1 409 vaccinated individuals we found a non-significant IgA/NT50 and IgG/NT50 correlation of Igs and NT50 values were not calculated for vaccinated individuals, since all antibody 419 titers were detected in the saturated range of the ELISA test. However, a significant 420 positive relation between total RBD-specific antibodies and NT50 values was found for 421 convalescent patients (data not shown). 422

Finally, we compared the efficacy of SARS-CoV-2 neutralization by sera from individuals 425 immunized with mRNA-or vector-based vaccines and convalescent patients for SARS-426

CoV-2 and circulating variants. For SARS-CoV-2 wild type strain we found that 79.0% of 427 recovered patients showed sufficient neutralization, while more than 94% of vaccinated 428 individuals could neutralize the wild type strain ( convalescent patients investigated serum IgG levels, but there is compelling evidence that 472 secretory and circulating IgA play an important role in immunity to . For 473 that reason, we here investigated IgG and IgA levels in serum samples of vaccinated and 474 convalescent individuals. We observed a robust IgG response to viral spike protein and 475

its RBD in all vaccinated participants, however the highest median antibody titers were 476 detected in both mRNA-based vaccines. This is in accordance with other published data, 477 which showed that two vaccine doses achieved high antibody titers across all ages using 478 J o u r n a l P r e -p r o o f 16 either ChAdOx1, BNT162b2 or mRNA1273 (23, 24). At the same time, we found that 479 antibody levels in convalescent patients have a high titer variation, which has been 480 previously reported and correlated with the duration and severity of clinical symptoms, but 481 not with patient age (25). 482

In case of SARS-CoV-2-specific serum IgA responses we could confirm highest titers in 483 mRNA-based vaccines compared to the vector-based vaccine or convalescent patients. 484

IgA antibodies are a heterogeneous group of Igs and occur in secretory, polymeric and 485 monomeric forms (26). Although recent studies demonstrated that there is only a weak 486 correlation between mucosal IgA and serum IgA antibodies, since they are mostly 487 generated locally in the salivary glands, some studies described that mucosal IgA were 488 even detectable in seronegative IgA convalescent patients (27) viruses for determining neutralization abilities, but novel SARS-CoV-2 variants with the 508 potential of higher transmission and more severe infection have emerged (21, 34, 35) . 509

Due to mutations in the RBD region of the viral spike protein, these VOCs or VOIs have 510 the potential to escape antibody binding and neutralization efficacy, which we analyzed 511 here using sera from vaccinated and convalescent individuals. We found that all three 512 investigated vaccines could neutralize Alpha-, Alpha-E484K, Beta-and Delta variant in 513 addition to SARS-CoV-2 wild type virus, but in some individuals only low or no 514 neutralization was detected. In our cohort neutralization against Alpha-E484K and Delta 515 variant was strongly reduced, especially in individuals immunized with vector-based 516

vaccine ChAdOx1. Other studies support our findings for Delta variant and observed an 517 efficacy of 88% for BNT162b2 and 67% for ChAdOx1 (36). Interestingly, we found an 518 BNT162b2). (24). In comparison, here we did not find differences of total Igs against RBD 530 between mRNA-1273 and BNT162b2 and detected higher IgG and IgA for BNT162b2. 531

Limitations of this study include the small number of study participants and the lack of data 532 on cellular immunity, which we previously investigated in COVID-19 patients with mild, 533 severe or critical disease progression (39). The impact of cellular immunity in protection 534 against infection and prevention of virus transmission has been studied and is still subject 535 of ongoing investigations (40, 41) . This is of importance since T cells might limit disease 536 progression in case of low neutralizing antibody levels and that generation of T cell 537 responses differ between mRNA-and vector-based vaccines (42, 43). Also, cellular 538 immunity in COVID-19 convalescent patients has to be determined in more detail, since 539 our data also showed, that antibody titers and neutralization ability ranged widely between 540 individuals of this group. Due to these heterogeneous results within the COVID-19 541 convalescent group, it is still very difficult to assess how and if protection of recovered 542 J o u r n a l P r e -p r o o f 18 individuals is facilitated. Novel COVID-19 vaccine formulations using various platforms 543 and new vaccine technologies are developed at the moment to deal with new challenges 544 against the current pandemic (44). New formulations also include nasal vaccine 545 application in an attempt to enhance innate and adaptive mucosal immunity (45). 546

Identifying whether novel vaccine candidates can also increase efficacy against emerging 547 (middle row) and mRNA-1273 (lower row). IgG antibody titer against SARS-CoV-2 S1 4 domain for immunized participants using ChAdOx1 (f=19; m=14), BNT162b2 (f=14; m=17) 5 and mRNA-1273 (f=14; m=9) were performed with the Anti-SARS-CoV-2-QuantiVac-6 ELISA (IgG) kit. Results for IgG are presented in binding antibody unit per ml serum 7 (BAU•ml -1 ). IgA antibody titers against SARS-CoV-2 S1 domain for vaccines were 8 performed with the Anti-SARS-CoV-2-ELISA (IgA) kit. Results for IgA are presented in 9 ratio of absorbance (RoA). Total Ig antibody titer against SARS-CoV-2 RBD immunized 10 participant were performed with the WANTAI SARS-CoV-2 Ab ELISA kit. Results for total 11

Igs are presented in ratio of absorbance (RoA). Statistical significance was determined by 12

Mann-Whitney-U test for nonparametric distribution. Anti-S1 IgG (Euroimmun)

Anti-S1 IgA (Euroimmun) 

Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. 585 Lancet

Progressive Increase in Virulence of Novel SARS-CoV-2 Variants 587 in Ontario

Evidence of escape 589 of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Reduced 592 neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

mRNA vaccine-595 elicited antibodies to SARS-CoV-2 and circulating variants

SARS-CoV-2 variant 597 B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

mRNA-1273 600 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. 601 bioRxiv

CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Covid-19: The E484K mutation and the risks it poses

Relationship 607 between selective IgA deficiency and COVID-19 prognosis

Antibody 610 responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United 611 Kingdom

Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Low serum 615 neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent 616 patients revealed by two different detection methods

Mucosal Immunity in COVID-19: A 619 Neglected but Critical Aspect of SARS-CoV-2 Infection

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe 623 COVID-19

IgA dominates the early 625 neutralizing antibody response to SARS-CoV-2

Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva

630 A mucosal antibody response is induced by intra-muscular SARS-CoV-2 mRNA vaccination

Relationship 633 between selective IgA deficiency and COVID-19 prognosis

Neutralizing 636 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 637 infection

Search 639 of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1

Assays in Pre-characterized Oligo-/Asymptomatic Patients. Infectious Diseases and Therapy

Identified Cases of SARS-CoV-2 Variant P.1 in the United States -Minnesota

Detection of a SARS-CoV-2 variant of concern in South Africa

648 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

651 Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and 652 Delta variant prevalence. medRxiv

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) 655 variant in Qatar

Potent 657 SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild 658 Disease Progression in COVID-19 Patients

Adaptive immunity to SARS-CoV-2 and COVID-19

BNT162b2 662 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Immunogenicity of clinically relevant SARS-CoV-2 665 vaccines in nonhuman primates and humans

Correlates of protection against SARS-CoV-2 in rhesus macaques

SARS-CoV-2 vaccines in development

Mucosal vaccines -fortifying the frontiers

Median NT50 (lower CL-upper CL at 95%)

Median NT90 (lower CL-upper CL at 95%)

CI 3.5-73.2) BNT162b2 Beta

) m-RNA1273 Alpha 996.5 (95% CI 564.6-1407.0) 345.5 (95% CI 245.4-504.6) m-RNA1273 Alpha

Convalescent WT 241

(95% CI 1.0-5.2) Convalescent Beta

Tab. S6 List of medians for neutralization titers J o u r n a l P r e -p r o o f